|
T.TH
|
This board is falling back in palaver mode. We all know that in official...
|
|
T.TH
|
I got that by email from LSA. They got my email from registering to listen to...
|
|
T.TH
|
In the last and recent article about TH1902 I focussed a lot on the fact that...
|
|
T.TH
|
After the linkers, my other special point of interest is the pharmacokinetic...
|
|
T.TH
|
Sorry, I also looked thouroughly at the patent, and nowhere it talks about...
|
|
T.TH
|
I agree it looks complicated, and in a way, it is, because what I thought was...
|
|
T.TH
|
OK. I foundother infos that could help a bit about the linker situation. In...
|
|
T.TH
|
Thank you SPCEO, I got the document. Now I have to agree with you, this was...
|
|
T.TH
|
Yes. It bumped. I found the good one on your website. SPCEO1 wrote: Perhaps...
|
|
T.TH
|
I agree that it's hard to believe that they would have made such a...
|
|
T.TH
|
As you will see with tese messages that I sent back in March, I made...
|
|
T.TH
|
After further readings in this almost endless patent covering as much ground...
|
|
T.TH
|
Thanks to confirm my recollection. No need to send it to me, but maybe you...
|
|
T.TH
|
Reading the article I noticed that the xenograft tumors on which TH1902 was...
|
|
T.TH
|
I went back to the patent and they show molecular pictures of the curcumin...
|
|
T.TH
|
It was in the investor day pdf presentation that they showed that the linker...
|
|
T.TH
|
It seems to be the case, unless I totally missed something, but I don't...
|
|
T.TH
|
I started to read the article, but just at the chemistry section I was...
|
|
T.TH
|
Another thing he said about efficacy, is that they don't want to report...
|
|
T.TH
|
Please stop bringing CYDY as an example of what Thera should do. They are...
|